High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study

Barsotti, Simone; Stagnaro, Chiara; d’Ascanio, A.; Parma, Alice; Emdin, Michele; Conti, Umberto; Mosca, Marta; Rossa, Alessandra Della

doi:10.5301/jsrd.5000244

Cited by 14 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NTproBNP-first-line diagnostic tool; follow-up; does not vary across skin subtypes [23]. Cut-off value of 130 pg/mL-sensitivity 74%, specificity 70%, NPV 85% for detecting cardiac impairment in SSc [23] cTn-positive correlation with cardiac disease in SSc, but with low specificity and sensitivity [46] ECG 25-75% SSc patients have abnormal tracings [39]. Independent predictor of mortality [39].…”

Section: Cardiac Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Sclerodermic Cardiomyopathy—A State-of-the-Art Review

et al. 2022

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic autoimmune disorder with unknown triggering factors, and complex pathophysiologic links which lead to fibrosis of skin and internal organs, including the heart, lungs, and gut. However, more than 100 years after the first description of cardiac disease in SSc, sclerodermic cardiomyopathy (SScCmp) is an underrecognized, occult disease with important adverse long-term prognosis. Laboratory tests, electrocardiography (ECG) and cardiovascular multimodality imaging techniques (transthoracic 2D and 3D echocardiography, cardiac magnetic resonance (CMR), and novel imaging techniques, including myocardial deformation analysis) provide new insights into the cardiac abnormalities in patients with SSc. This state-of-the-art review aims to stratify all the cardiac investigations needed to diagnose and follow-up the SScCmp, and discusses the epidemiology, risk factors and pathophysiology of this important cause of morbidity of the SSc patient.

show abstract

Section: Cardiac Biomarkersmentioning

confidence: 99%

“…Cardiac troponins (cTn) are sarcomeric regulatory proteins with high specificity for myocardial tissue. According to Barsotti et al, high levels of high-sensitivity cTn (hs-cTn) are positively correlated with cardiac disease in SSc, but with low specificity and sensitivity (83%, 66.7%) [46].…”

Section: Cardiac Biomarkersmentioning

confidence: 99%

Sclerodermic Cardiomyopathy—A State-of-the-Art Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…16 There is emerging evidence of a role for more sensitive diagnostic techniques such as tissue Doppler echocardiography (TDE) and cardiac magnetic resonance imaging (CMR), 17 and for biomarkers such as N-terminal pro B-type natriuretic peptide, 18 and high-sensitivity cardiac troponin. 19,20 However, the clinical significance of abnormalities detected by newer investigation modalities remains uncertain.…”

Section: Cardiac Wgpi: Authors Av (Alessandra Vacca) Lr Mb Amentioning

confidence: 99%

An interim report of the Scleroderma Clinical Trials Consortium working groups

Baron

Kahaleh

Bernstein

et al. 2018

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis (SSc). The SCTC has established 11 working groups (WGs) to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the SCTC may join any one or more of these groups. Some of the WGs have only recently started their work, some are nearing completion of their mandated tasks and others are in the midst of their projects. All these projects, which are described in this paper, will help to improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The SCTC is dedicated to improving the lives of patients with SSc and it is our hope that the contributions of the WGs will be one important step in this process.

show abstract

“…Heart involvement is frequent and is a major cause of mortality in systemic sclerosis (SSc), being responsible for up to 30% of disease-related deaths (1)(2)(3). Heart involvement has a variable clinical presentation: at early stages most patients are asymptomatic, but some go on to develop arrhythmias, dyspnea, chest pain, and heart failure (HF) (1,(4)(5)(6)(7)(8)(9). In comparison to other inflammatory myocardial disease, myocardial fibrosis is usually considered the immunopathologic hallmark of SSc heart disease.…”

Section: Introductionmentioning

confidence: 99%

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement

et al. 2021

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is rare, severe connective tissue disease characterized by endothelial and vascular damage, immune activation, and resulting in inflammation and fibrosis of skin and internal organs, including the heart. SSc is associated with high morbidity and mortality. Cardiac involvement is frequent in SSc patients, even though often asymptomatic at early stages, and represents one of the major causes of SSc-related mortality. Heart involvement has a variable clinical presentation, and its pathogenesis is not completely understood. Myocardial fibrosis is traditionally considered the immunopathologic hallmark of heart involvement in SSc. This unique histological feature is paralleled by distinctive clinical and prognostic features. The so-called “vascular hypothesis” represents the most credited hypothesis to explain myocardial fibrosis. More recently, the prominent role of an inflammatory myocardial process has been identified as a cardinal event in the evolution to fibrosis, thus also delineating an “inflammation-driven pathway to fibrosis”. The pro-inflammatory cytokine interleukin (IL)-1 has an apical and cardinal role in the myocardial inflammatory cascade and in cardiac dysfunction. The primary aim of this perspective article is: to present the emerging evidence on the role of IL-1 and inflammasome in both SSc and heart inflammation, to review the complex interplay between cellular metabolism and inflammasome activation, and to discuss the rationale for targeted inhibition of IL-1 for the treatment of SSc-heart involvement, providing preliminary experimental and clinical data to support this hypothesis.

show abstract

High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study

Cited by 14 publications

References 16 publications

Sclerodermic Cardiomyopathy—A State-of-the-Art Review

Sclerodermic Cardiomyopathy—A State-of-the-Art Review

An interim report of the Scleroderma Clinical Trials Consortium working groups

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement

Contact Info

Product

Resources

About